Boehringer kickstarts two Phase III trials as MASH therapy wins breakthrough status

Boehringer kickstarts two Phase III trials as MASH therapy wins breakthrough status

Source: 
Clinical Trials Arena
snippet: 

Boehringer Ingelheim has received a breakthrough therapy designation from the US Food and Drug Administration (FDA) for survodutide as a treatment for non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis.